University of Cambridge researchers and their spin-out DIOSynVax completed the first human clinical trial of a universal vaccine aimed at Sarbeco coronaviruses, including SARS-CoV-2-related viruses. The study, centered on broad-spectrum targeting, reported early safety and established a clinical proof point for a platform designed to address future coronavirus outbreaks. In parallel, MIT-led work reported an experimental injectable polio vaccine adjuvant strategy designed to induce mucosal immunity, addressing a key limitation of inactivated polio vaccines: reduced ability to block transmission compared with oral formulations. Using Am80 delivered via lipid nanoparticles, the approach aims to lower viral shedding while maintaining the safety profile associated with injectable polio vaccines. Together, the developments underscore a two-pronged push in vaccinology: expanding breadth ahead of emerging pathogens and improving transmission-blocking immune responses without reverting to higher-risk administration formats.